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Defibrination with ancrod in nephrotoxic nephritis in rabbits. In
rabbits with nephrotoxic nephritis, defibrination with ancrod pro-
vided protection when administered during the autologous phase,
after extensive glomerular fibrin deposition had occurred and cres-
cents and renal failure were developing. When further glomerular
fibrin deposition was prevented by defibrination, deposited fibrin
was rapidly removed, indicating that glomerular fibrin-clearing
mechanisms are retained in crescentic nephritis. Defibrination had
no effect on the extent of glomerular C3 deposition or on the
amount of proteinuria.
Défibrination par I'ancrod dans Ia néphrite nephrotoxique (NTN)
chez le lapin. La défibrination par l'ancrod chez des lapins atteints
de néphrite néphrotoxique determine une protection quand elle est
réalisée au cours de Ia phase autologue, aprés que des dépôts de
fibrine importants soient apparus et alors que des croissants et une
insuffisance rénale se développent. Quand l'accroissement des dé-
pots de fibrine est prCvenu par Ia dCfibrination Ia fibrine déjà
dCposCe disparalt rapidement, ce qui indique que les mécanismes
d'élimination de Ia fibrine sont conserves dans Ia néphrite avec
croissants. La dCflbrination n'a d'effet ni sur Ia deposition gb-
mCrulaire de C3 ni sur Ic debit de Ia protéinurie.
In previous studies we have demonstrated that
defibrination with ancrod (Arvin®), the coagulant
fraction of Malayan pitviper venom, provided re-
markable protection in experimental allergic glomer-
ulonephritis in rabbits: both in nephrotoxic nephritis
and in chronic bovine-serum-albumin (BSA)-induced
serum sickness, glomerular fibrin deposition, crescent
formation and renal failure were substantially re-
duced [1-3]. Furthermore, such defibrination was
shown to be more protective than massive doses of
heparin. However, in these experiments and in most
other reports [4-8] on the effects of anticoagulants in
experimental nephritis, therapy had been started be-
fore the glomerular deposition of fibrin and the con-
sequent extracapillary cell proliferation had taken
place.
In this paper we report studies in rabbits of the
effects of defibrination in nephrotoxic nephritis when
therapy was started at the stage when proliferation
and uremia were developing, after extensive glomeru-
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lar deposition of fibrin had occurred. We have also
undertaken experiments designed to assess the capac-
ity of the glomerulus to remove deposited fibrin. Our
observations show that defibrination provides re-
markable protection provided that renal failure is not
too far advanced; this protection may be related to
our second finding, namely that in defibrinated ani-
mals deposited fibrin is rapidly removed from the
injured glomerulus.
Methods
Animals. Male New Zealand white rabbits weigh-
ing 2 to 2.5 kg and fed on a normal water and pellet
diet were used.
Preparation, characterization and administration of
nephrotoxic serum. The sheep anti-rabbit glomerular
basement membrane (GBM) antiserum (nephrotoxic
serum) has been characterized previously [2]. The
i.v. injection of 1 ml/kg of this antiserum (NTS)
resulted in the deposition of approximately 180 tg of
nephrotoxic antibody per kidney.
Defibrination. Defibrination was induced with an-
crod, 0.5 it/kg administered i.v., followed one hour
later by 1.0 U/kg and maintained with the twice-daily
i.v. injection of 1.0 to 2.0 U/kg. Adequacy of defibri-
nation was assessed by the clot-quality test [9].
Serum and urine samples. Concentrations of serum
creatinine were determined by the auto-analyzer
method and urine protein by the Biuret method.
Histological and immunofluorescent preparations.
Portions of kidney were fixed in 10% buffered form a-
un, sectioned at 4 t and stained with hematoxylin-
eosin, periodic acid-Schiff and Martius scarlet blue
(MSB) stains. Specimens were also snap-frozen in
liquid nitrogen, sectioned at 4 on a cryostat and
stained with fluorescein isothiocyanate (FITC) con-
jugated antisera to sheep IgG, rabbit IgG, rabbit C3
and rabbit fibrin. All antisera were prepared in our
laboratory and conjugated with FITC as described by
Fothergill [10].
Assessment of the histological and immunofluores-
cent preparations. Sections were coded and analysis
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Days
Fig. 1. Serum creatinine concentrations (mg/100 ml) on days 6 to 24
in control animals (A——A) and animals treated with ancrod as
from day 10 (J——).
was based on independent ("blind") assessment as
described previously {2J. Extracapillary cell pro-
liferation was assessed by light microscopy, each
glomerulus being scored from 0 to 3 as follows: a
score of 0 represented no crescent formation; scores
of 1, 2 and 3 represented the involvement of one-
third, one-third to two-thirds and two-thirds of the
circumference of the glomerulus, respectively, by pro-
liferating extracapillary cells. Fibrin deposition (on
immunofluorescent examination) was also scored
from 0 to 3 for each glomerulus, a score of 0 repre-
senting no fibrin and scores of 1, 2 and 3 representing
fibrin deposition visually assessed to be involving
one-third, one-third to two-thirds and two-thirds, re-
spectively of the surface area of glomerular tuft and
crescent. At least 50 glomeruli per animal were as-
sessed by light microscopy and 30 glomeruli by im-
munofluorescence. Mean scores for extracapillary
cellular proliferation and fibrin deposition were then
determined for each animal.
Statistical analysis. Data was analyzed by using the
Wilcoxon rank test for two samples [11].
Experimental protocols. A. This protocol was de-
signed to examine the protective effect of defibrina-
tion commenced after extensive fibrin deposition had
already occurred. Eighteen rabbits were injected i.v.
with 1 ml/kg or NTS on day 0. Nine animals were
defibrinated with ancrod from day 10 of the disease
until death or cessation of the experiment on day 24.
Nine control animals were given similar volumes of
saline i.v. from day 10. Animals were bled on alter-
nate days and urine samples obtained on alternate
days by urethral catheterization. Surviving animals
were killed on day 24 and their kidneys removed for
histology and examination by immunofluorescence.
B. This protocol was designed to examine the ca-
pacity of the glomerulus to remove deposited fibrin.
Thirty-four rabbits were injected i.v. with 1 mI/kg of
NTS (day 0). Fourteen animals were defibrinated
from day 10, the remainder receiving saline. Animals
from the defibrinated and the control groups were
killed on various days from day 10 and glomerular
flbrin deposition was assessed.
Results
ProtocolA. 1. Renalfunction. Figure 1 shows that if
the serum creatinine concentration on day 10 was
greater than 8 mg/l00 ml the outlook was bad irres-
pective of whether the animal was defibrinated or
not. Thus, three of five animals (two treated and one
control) with serum creatinine concentrations greater
than 8 mg/lOO ml on day 10 died from renal failure.
It was therefore decided to analyze the results of
defibrination in animals in whom the serum creati-
nine was less than 8 mg/l00 ml on day 10, the day on
which defibrination was started. When this was done,
a highly significant reduction in serum creatinine (evi-
dent from day 16) was found in the defibrinated
group (six animals) when compared to controls
(seven animals) (Table 1, Fig. 2).
2. Immunofluorescence. a. Immunoglobulins and C3.
Linear deposition of sheep IgG, rabbit IgG and rab-
bit C3, along the GBM was seen in all animals. No
Table 1. Serum creatinine concentrations on days 10 to 24 in control and ancrod-treated animals in which serum creatinine
concentrations were less than 8 mg/100 ml on day l0a
Animal
group N
Serum creatinine, mg/100 ml
Day 10 Day 12 Day 14 Day 16 Day 18 Day2O Day22 Day24
Control 6 3.79
(1.8—6.5)
5.83
(2.1—9.6)
6.76
(3.0—12.1)
7.40
(2.5—17.4)
7.64
(2.5—19.5)
7.10
(2.3—19.1)
6.84
(2.5—19.7)
7.21
(2.2—22.2)
Ancrod-treated 7 4.53
(2.5—7.1)
4.57
(1.8—8.4)
4.35
(1.3—6.0)
2.75b
(1.1—5.1)
2.15C
(1.2—4.0)
2.08C
(1.0—3.1)
l.92C
(1.1—3.0)
1.82C
(1.0—3.1)
Values are the mean and (range).
P < 0.02.
P < 0.01.
26
24
16
14
12
C)
E 10
C)
E
a)(I) 2
0
(45.0)
•{\\\\/
.
IIz///f // . .
2 4 6 8 10 12 14 16 18 20 22 24 26
Defibrinazion in nephrotoxic nephritis 345
difference in intensity of staining was evident between
the groups of animals.
b. Fibrin. There was marked fibrin deposition in the
control animals on day 10 (mean fibrin score, 1.97)
and slightly less on day 12 (mean fibrin score, 1.81).
Only flecks of fibrin were detected in either control or
treated animals on day 24 (Fig. 3).
Protocol B. In control animals there appeared to be
a steady reduction in the glomerular fibrin deposits
with time. By day 24 only flecks of fibrin were seen by
immunofluorescence or MSB staining. There was a
striking difference in animals defibrinated from day
10, the reduction in glomerular fibrin being more
rapid, such that fibrin was not detected in the glome-
ruli of animals killed after day 14 (Fig. 3).
Discussion
These experiments have shown that crescent for-
mation and renal failure can be reduced in NTN by
defibrination instituted at a stage when renal failure
has developed, provided the serum creatinine concen-
tration is not more than 8 mg/lOO ml. As might be
expected, this protection is not as great as that fol-
lowing defibrination before glomerular fibrin deposi-
tion [2]. However, the present experiments are ob-
viously of more relevance to human anti-GBM
disease, where it is more likely that significant gb-
merular damage will have occurred before therapy is
begun.
Only two investigators have described the effect of
anticoagulation commenced during the autologous
or delayed phase of NTN. Kleinerman [5] was unable
to demonstrate protection even when massive doses
of heparin were administered in rabbits, although the
same doses of heparin were protective when adminis-
tered before the induction of disease. This difference
may be related to the superiority of ancrod over
Day
Fig3. Glomerularfibrin scores in control (fl) and ancrod-treated (U)
animals killed on successive days. Ancrod administration was be-
gun on day 10. The scores in the control group on day 12 are those
obtained from our own previously published experiments using
identical doses of the same nephrotoxic serum [21.
standard anticoagulant doses of heparin in protecting
the glomerulus in nephrotoxic nephritis in rabbits [2].
Borrero et al [12] have found protection in hares with
NTN by warfarin started after the disease had been
present for two weeks. However, these workers were
obviously dealing with a disease model of lesser se-
verity, as shown by a mean maximum blood urea
nitrogen concentration in their control animals of 49
mg/100 ml; a further point of some practical signifi-
cance is that one-third of warfarin-treated animals
died of hemorrhage.
Recent experiments in rabbits [7] and in the rat [8]
have confirmed the ineffectiveness of heparin in se-
vere nephrotoxic nephritis, even when commenced at
the time of injection of the nephrotoxic antibody (i.e.,
before any glomerular damage has occurred). In con-
trast, in previous experiments we have shown the
marked protected value of defibrination commenced
at this stage [2]. Comparable protection was given
2 only by massive doses of heparin (2000 U/kg/day).
Depleting the animal of complement, polymorphs,
8 or fibrinogen produces strikingly different effects.
Defibrination, while protecting against fibrin deposi-
tion, crescent formation and renal failure, had no
influence on proteinuria or glomerular C3 deposition.
Lately we have shown [13], using a "telescoped"
model of nephrotoxic nephritis in rabbits that com-
plement depletion with CVF, while almost com-
pletely preventing gbomerular deposition of C3, does
not protect against glomerular fibrin deposition, cres-
cent formation, renal failure or proteinuria.
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Fig. 2. Serum creasinine concentrations ) and crescent scores ()
on day 24, in control and ancrod-treated animals in which the serum
creatinine concentration had been less than 8 mg/lOO ml on day 10.
There is a significant reduction in the ancrod-treated animals (P =
0.02).
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Table 2. Mean urine protein concentrations in control and ancrod-treated animals in which serum creatinine concentrations were
less than 8 mg/tOO ml on day ioa
.Animal
group N
Urine protein concentration, mg/mi
DayO Day 10 Day 12 Day 16 Day 20 Day 24
Control 6 <0.3 12.6
(2.1—27)
7.2
(1.8—18)
5.9
(1.2—10.5)
4.4
(2.1—8.5)
3.8
(1.9—6.8)
Ancrod-treated 7 <0.3 9.8
(1.9—17)
8.1
(1.6—12)
6.4
(1.8—14.2)
3.2
(1.6—5.9)
2.9
(1.2—4.5)
Values are the mean and (range).
On the other hand, using the same model, poly-
morph depletion with antipolymorph serum pro-
duced substantial protection against fibrin deposi-
tion, crescent formation, renal failure and
proteinuria, while not affecting glomerular C3 depo-
sition. It therefore appears incorrect to state, as do
Border, Wilson and Dixon [7], that "neutrophil inde-
pendence and dependence are im munopathologically
synonymous with complement independence and de-
pendence," at least in the autologous or delayed
phase of nephrotoxic nephritis.
Our second series of experiments were designed to
examine the disappearance of the glomerular deposits
of fibrin. We found that in untreated animals there
was a steady reduction in glomerular fibrin deposits
so that by day 24 fibrin became virtually undetectable
in all animals. However, in defibrinated animals,
fibrin was no longer detected in the glomeruli after
day 14, indicating that when further fibrin deposition
is prevented the glomerulus is capable of clearing its
fibrin deposits rapidly. These observations suggest
that the glomerular fibrin-clearing mechanisms still
function in severe crescentic nephritis.
It is unclear to what extent this ability to remove
deposited fibrin is dependent on local fibrinolysis:
although renal vascular endothelium has been dem-
onstrated to have considerable fibrinolytic potential
[14], for anatomical reasons, this endothelial activity
may be without effect on the fibrin deposited in Bow-
man's space. Another possible mechanism for clear-
ance of deposited fibrin is phagocytosis. In this con-
nection recent evidence [15,161 suggests that the
principal cells constituting crescents are not of epithe-
hal origin but ar infiltrating monocytic cells—con-
trary to earlier views [17]. It has been postulated that
such cells accumulate as a phagocytic response to
fibrin deposition.
Whatever is the responsible mechanism, these re-
sults, taken in conjunction with our previous data [I-
3] (which indicate that ancrod is superior to heparin
in nephrotoxic nephritis and is protective in chronic
BSA-induced immune complex nephritis in rabbits)
suggest that a trial of defibrination in human cres-
centic nephritis would be timely. In this connection it
is of interest that during plasma exchange using
plasma protein fraction, removal of fibrinogen oc-
curs; this may be at least partly responsible for the
benefit of this therapy [18]. In patients with normal
renal function, ancrod has been shown to be a safe
and effective anticoagulant [19]. However, its safety
in patients with renal failure with its attendant im-
paired platelet function remains to be established.
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